Latest Earnings Results: Q3 '26
Estimated EPS
$0.89
Reported EPS
$0.94
Surprise
+5.96%
Estimated Rev
$646.51M
Reported Rev
$658.7M
Surprise
+1.88%
• Reported GAAP EPS of $0.94 up 20.51% YoY • Reported revenue of $658.7M up 10.20% YoY • Exelixis FY2026 guidance maintains total revenues of $2.5B - $2.55B and net product revenues of $2.3B - $2.35B; effective tax rate is 16% - 18%, versus 21% - 23% previously.
Bullish Takeaway
Exelixis Q3 cabozantinib product revenues increased with higher sales volume and average net selling price; STELLAR-303 met an overall-survival endpoint and zanzalintinib studies were initiated and enrolling.
Bearish Takeaway
Exelixis CRC NDA review was extended three months, with a non-statistically significant OS trend in the NLM subpopulation; R&D and SG&A expenses rose, and generic competition remains a stated risk.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | $0.96 | -- | -- | N/A |
Q3 '26 | $0.89 | $0.94 | 5.96% | BEAT |
Q2 '26 | $0.85 | $0.91 | 6.63% | BEAT |
Q1 '26 | $0.76 | $0.87 | 13.76% | BEAT |
Q4 '25 | $0.83 | $0.94 | 13.31% | BEAT |